In a striking revelation, internal records have surfaced detailing a June 2025 meeting between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. This encounter focused on legal strategies concerning glyphosate, the active ingredient in Roundup, amidst ongoing litigation alleging that the herbicide causes cancer. The meeting, which took place just months before the Trump administration took significant actions to bolster Bayer’s position in court, has triggered concerns over the influence of corporate interests on public health regulations.
Corporate Lobbying and Legal Strategies
The 17 June meeting included discussions about litigation matters, particularly Bayer’s efforts to mitigate the impact of lawsuits filed by thousands of individuals claiming health risks associated with glyphosate usage. These lawsuits contend that Bayer neglected to adequately inform consumers about the potential cancer risks linked to its products. The company aims to convince the Supreme Court that if the EPA does not mandate a cancer warning on glyphosate labels, it should not be held liable for failing to provide such warnings.
Notably, while an appellate court ruled in favour of Bayer’s argument, other courts have dismissed it, including under the Biden administration. Conversely, the Trump administration has consistently supported Bayer’s stance, indicating a troubling alignment between corporate interests and governmental policy.
Transparency and Accountability in Regulatory Processes
Bayer defended the meeting, characterising it as a standard aspect of regulatory engagement, stating that the company has been open about its position concerning glyphosate litigation. However, the details of the meeting raise questions about the transparency of the regulatory process. Internal communications indicate that Bayer intended to discuss “legal/judicial issues,” prompting criticism from environmental advocates.
Nathan Donley, an environmental health science director at the Center for Biological Diversity, voiced concerns about the meeting, suggesting it exemplifies a troubling trend where political appointees prioritise corporate profits over public health. He highlighted the disparity in access to regulatory discussions, questioning whether affected individuals have been afforded similar opportunities to engage with the EPA.
Recent Actions Bolstering Bayer’s Legal Position
The Trump administration’s backing of Bayer has manifested in various ways since the June meeting. On 1 December 2025, the solicitor general appointed by Trump urged the Supreme Court to hear Bayer’s case, a request that the Court subsequently granted, scheduling a hearing for 27 April. Furthermore, the administration invoked the Defense Production Act in February 2026 to safeguard glyphosate production, effectively shielding Bayer from potential liabilities.
The government’s support has extended to filing an amicus brief in March 2026, which further solidified the administration’s endorsement of Bayer’s legal arguments. Environmental advocates and legal experts alike have expressed concern over these developments, raising alarms about the implications of corporate influences on regulatory decisions.
The Public’s Right to a Voice
Legal experts have critiqued the nature of the meeting, suggesting that it is alarming for a major pesticide company’s CEO to have direct discussions with the EPA about limiting liability while those harmed by the product remain unheard. Whitney Di Bona, a consumer safety advocate, emphasised the need for accountability, questioning whether the EPA has afforded similar opportunities for dialogue to those who claim to have suffered from glyphosate-related health issues.
This situation reflects a broader pattern of industry leaders gaining access to government officials in ways that ordinary citizens cannot. Naomi Oreskes, a Harvard professor studying corporate influence, highlighted the disparity in access, suggesting a systemic bias that prioritises corporate interests over public welfare.
Why it Matters
This incident underscores a critical moment in the ongoing struggle between corporate power and public health. As the Trump administration aligns itself with Bayer, it raises fundamental questions about regulatory integrity and the prioritisation of public interest. The implications of these decisions extend far beyond legal battles; they touch upon the health and safety of millions who rely on regulatory agencies to protect them from harmful products. As citizens, we must advocate for transparency and accountability in governmental processes to ensure that our health is not compromised in favour of corporate profits.
